Synaptic Defects in the Spinal and Neuromuscular Circuitry in a Mouse Model of Spinal Muscular Atrophy

Karen Ling, Ming-Yi Lin, Brian Zingg, Zhihua Feng, Chien‐Ping Ko

PLoS ONE · 2010 · 215 citations · 47 references

DOIFull text

Open access

Concepts

TL;DR

Spinal muscular atrophy is a leading genetic cause of childhood death, marked by profound muscle weakness. This study examined the spinal and neuromuscular circuitry underlying hindlimb locomotion in SMNΔ7 mice to uncover mechanisms of motor impairment. The authors found that although neuromuscular junctions remained fully innervated, there was a 28 % loss of synapses onto lumbar motoneurons, a 50 % reduction in VGLUT1‑positive proprioceptive inputs, and increased microglial association, indicating widespread synaptic defects that may be targeted therapeutically.

Abstract

Spinal muscular atrophy (SMA) is a major genetic cause of death in childhood characterized by marked muscle weakness. To investigate mechanisms underlying motor impairment in SMA, we examined the spinal and neuromuscular circuitry governing hindlimb ambulatory behavior in SMA model mice (SMNΔ7). In the neuromuscular circuitry, we found that nearly all neuromuscular junctions (NMJs) in hindlimb muscles of SMNΔ7 mice remained fully innervated at the disease end stage and were capable of eliciting muscle contraction, despite a modest reduction in quantal content. In the spinal circuitry, we observed a ∼28% loss of synapses onto spinal motoneurons in the lateral column of lumbar segments 3–5, and a significant reduction in proprioceptive sensory neurons, which may contribute to the 50% reduction in vesicular glutamate transporter 1(VGLUT1)-positive synapses onto SMNΔ7 motoneurons. In addition, there was an increase in the association of activated microglia with SMNΔ7 motoneurons. Together, our results present a novel concept that synaptic defects occur at multiple levels of the spinal and neuromuscular circuitry in SMNΔ7 mice, and that proprioceptive spinal synapses could be a potential target for SMA therapy.

References

47